Literature DB >> 23277917

Chemokine programming dendritic cell antigen response: part II - programming antigen presentation to T lymphocytes by partially maintaining immature dendritic cell phenotype.

Jaehyung Park1, James D Bryers.   

Abstract

In a companion article to this study,(1) the successful programming of a JAWSII dendritic cell (DC) line's antigen uptake and processing was demonstrated based on pre-treatment of DCs with a specific 'cocktail' of select chemokines. Chemokine pre-treatment modulated cytokine production before and after DC maturation [by lipopolysaccharide (LPS)]. After DC maturation, it induced an antigen uptake and processing capacity at levels 36% and 82% higher than in immature DCs, respectively. Such programming proffers a potential new approach to enhance vaccine efficiency. Unfortunately, simply enhancing antigen uptake does not guarantee the desired activation and proliferation of lymphocytes, e.g. CD4(+) T cells. In this study, phenotype changes and antigen presentation capacity of chemokine pre-treated murine bone marrow-derived DCs were examined in long-term co-culture with antigen-specific CD4(+) T cells to quantify how chemokine pre-treatment may impact the adaptive immune response. When a model antigen, ovalbumin (OVA), was added after intentional LPS maturation of chemokine-treated DCs, OVA-biased CD4(+) T-cell proliferation was initiated from ~ 100% more undivided naive T cells as compared to DCs treated only with LPS. Secretion of the cytokines interferon-γ, interleukin-1β, interleukin-2 and interleukin-10 in the CD4(+) T cell : DC co-culture (with or without chemokine pre-treatment) were essentially the same. Chemokine programming of DCs with a 7 : 3 ratio of CCL3 : CCL19 followed by LPS treatment maintained partial immature phenotypes of DCs, as indicated by surface marker (CD80 and CD86) expression over time. Results here and in our companion paper suggest that chemokine programming of DCs may provide a novel immunotherapy strategy to obviate the natural endocytosis limit of DC antigen uptake, thus potentially increasing DC-based vaccine efficiency.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277917      PMCID: PMC3634541          DOI: 10.1111/imm.12059

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  56 in total

Review 1.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 2.  Vaccine protocols for enhanced immunogenicity of exogenous antigens.

Authors:  Antje Heit; Dirk H Busch; Hermann Wagner; Frank Schmitz
Journal:  Int J Med Microbiol       Date:  2007-09-20       Impact factor: 3.473

Review 3.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

4.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Authors:  Nicholas S Wilson; Dima El-Sukkari; Gabrielle T Belz; Christopher M Smith; Raymond J Steptoe; William R Heath; Ken Shortman; José A Villadangos
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

5.  Secretion of interleukin-10 or interleukin-12 by LPS-activated dendritic cells is critically dependent on time of stimulus relative to initiation of purified DC culture.

Authors:  Hui-Rong Jiang; Elizabeth Muckersie; Marie Robertson; Heping Xu; Janet Liversidge; John V Forrester
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 6.  Activation-induced cell death in T cells.

Authors:  Douglas R Green; Nathalie Droin; Michael Pinkoski
Journal:  Immunol Rev       Date:  2003-06       Impact factor: 12.988

7.  A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.

Authors:  Amy Sexton; Paul G Whitney; Siow-Feng Chong; Alexander N Zelikin; Angus P R Johnston; Robert De Rose; Andrew G Brooks; Frank Caruso; Stephen J Kent
Journal:  ACS Nano       Date:  2009-11-24       Impact factor: 15.881

8.  The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.

Authors:  Tatsuya Fujioka; Yuki Taniguchi; Tomoki Masuda; Sumiyuki Nishida; Kazuhiro Ikegame; Manabu Kawakami; Akihiro Tsuboi; Naoki Hosen; Masaki Murakami; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama; Ichiro Kawase; Hiroyasu Ogawa
Journal:  Transpl Immunol       Date:  2003 Apr-Jun       Impact factor: 1.708

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming.

Authors:  Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.